554448-74-7Relevant academic research and scientific papers
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: Synthesis, pharmacokinetics, and in vivo potency
Borthwick, Alan D.,Liddle, John,Davies, Dave E.,Exall, Anne M.,Hamlett, Christopher,Hickey, Deirdre M.,Mason, Andrew M.,Smith, Ian E. D.,Nerozzi, Fabrizio,Peace, Simon,Pollard, Derek,Sollis, Steve L.,Allen, Michael J.,Woollard, Patrick M.,Pullen, Mark A.,Westfall, Timothy D.,Stanislaus, Dinesh J.
, p. 783 - 796 (2012/03/11)
A six-stage stereoselective synthesis of indanyl-7-(3′-pyridyl)-(3R, 6R,7R)-2,5-diketopiperazines oxytocin antagonists from indene is described. SAR studies involving mono- and disubstitution in the 3′-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pKi > 9.0) with good aqueous solubility. Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2′,6′-dimethyl-3′- pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pKi = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition. Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.
2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency
Borthwick, Alan D.,Davies, Dave E.,Exall, Anne M.,Hatley, Richard J. D.,Hughes, Jennifer A.,Irving, Wendy R.,Livermore, David G.,Sollis, Steve L.,Nerozzi, Fabrizio,Valko, Klara L.,Allen, Michael J.,Perren, Marion,Shabbir, Shalia S.,Woollard, Patrick M.,Price, Mark A.
, p. 4159 - 4170 (2007/10/03)
A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured li
NOVEL COMPOUNDS
-
Page/Page column 17-18, (2008/06/13)
Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2, 6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS
-
Page/Page column 17-18, (2010/02/15)
Compounds of formula (I); wherein R1 is 2-indanyl, R2 is 1-ethylpropyl, R3 is a heterocyclic group optionally substituted by one or more C1-6 alkyl groups, R4 represents methyl and R5 repre
